CYCN vs. BRNS, ATHE, RAPT, INKT, QTTB, ESLA, ANVS, TPST, CASI, and ITRM
Should you be buying Cyclerion Therapeutics stock or one of its competitors? The main competitors of Cyclerion Therapeutics include Barinthus Biotherapeutics (BRNS), Alterity Therapeutics (ATHE), RAPT Therapeutics (RAPT), MiNK Therapeutics (INKT), Q32 Bio (QTTB), Estrella Immunopharma (ESLA), Annovis Bio (ANVS), Tempest Therapeutics (TPST), CASI Pharmaceuticals (CASI), and Iterum Therapeutics (ITRM). These companies are all part of the "pharmaceutical products" industry.
Cyclerion Therapeutics vs.
Cyclerion Therapeutics (NASDAQ:CYCN) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, community ranking, dividends, valuation, institutional ownership and earnings.
Barinthus Biotherapeutics has a consensus target price of $5.17, indicating a potential upside of 416.67%. Given Barinthus Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Barinthus Biotherapeutics is more favorable than Cyclerion Therapeutics.
Cyclerion Therapeutics has higher revenue and earnings than Barinthus Biotherapeutics.
Cyclerion Therapeutics has a beta of 1.74, meaning that its share price is 74% more volatile than the S&P 500. Comparatively, Barinthus Biotherapeutics has a beta of -0.82, meaning that its share price is 182% less volatile than the S&P 500.
In the previous week, Cyclerion Therapeutics' average media sentiment score of 0.00 equaled Barinthus Biotherapeutics'average media sentiment score.
75.6% of Cyclerion Therapeutics shares are held by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are held by institutional investors. 36.1% of Cyclerion Therapeutics shares are held by insiders. Comparatively, 8.0% of Barinthus Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Cyclerion Therapeutics received 19 more outperform votes than Barinthus Biotherapeutics when rated by MarketBeat users. However, 100.00% of users gave Barinthus Biotherapeutics an outperform vote while only 58.62% of users gave Cyclerion Therapeutics an outperform vote.
Barinthus Biotherapeutics' return on equity of -34.26% beat Cyclerion Therapeutics' return on equity.
Summary
Barinthus Biotherapeutics beats Cyclerion Therapeutics on 7 of the 13 factors compared between the two stocks.
Get Cyclerion Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CYCN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cyclerion Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CYCN) was last updated on 2/22/2025 by MarketBeat.com Staff
Free CYCN Stock Alerts